Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection
暂无分享,去创建一个
Hanneke Schuitemaker | Evelien M. Bunnik | E. Bunnik | H. Schuitemaker | Ad C. van Nuenen | Linaida Pisas | L. Pisas | A. V. van Nuenen
[1] Yang Liu,et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] W. Blattner,et al. Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course , 2001, Journal of Virology.
[3] G. Groen,et al. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag. , 1989, Virology.
[4] J. Overbaugh,et al. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies , 1997, Journal of virology.
[5] E. Fenyö,et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. , 1997, The Journal of infectious diseases.
[6] J. Sodroski,et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.
[7] T. A. Hall,et al. BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .
[8] J. Mascola,et al. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.
[9] L. Stamatatos,et al. An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades , 1998, Journal of Virology.
[10] J. Margolick,et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.
[11] A Muñoz,et al. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. , 1999, The Journal of infectious diseases.
[12] Jun Li,et al. Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.
[13] D. Montefiori,et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.
[14] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[15] J. M. González,et al. A fluorimetric method for the estimation of G+C mol% content in microorganisms by thermal denaturation temperature. , 2002, Environmental microbiology.
[16] D. Nickle,et al. Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host , 2006, Journal of Virology.
[17] Sergei L. Kosakovsky Pond,et al. Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics , 2007, PLoS Comput. Biol..
[18] J. Overbaugh,et al. Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.
[19] H. Schuitemaker,et al. Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs , 2008, PloS one.
[20] Don C. Wiley,et al. Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.
[21] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[22] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[23] Amanda M. Brown,et al. Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation , 1999, Journal of Virology.
[24] L. Stamatatos,et al. The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner , 2005, Journal of Virology.
[25] H. Katinger,et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.
[26] Christos J. Petropoulos,et al. Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses , 2006, Journal of Virology.
[27] B. Korber,et al. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. , 2004, Virology.
[28] Hui Li,et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[29] Robert F. Siliciano,et al. Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations , 2006, The Journal of experimental medicine.
[30] F. Bibollet-Ruche,et al. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.
[31] Christos J. Petropoulos,et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus , 2006, The Journal of experimental medicine.
[32] H. Schuitemaker,et al. Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies , 2007, Journal of Virology.
[33] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[34] C. Bustamante,et al. A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients. , 2005, Molecular biology and evolution.
[35] B. Walker,et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. , 1996, AIDS research and human retroviruses.
[36] H. Schuitemaker,et al. Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker , 2004, Journal of Virology.
[37] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[38] Peter D. Kwong,et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.
[39] Bette Korber,et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.
[40] H. Schuitemaker,et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. , 2003, The Journal of infectious diseases.
[41] D. Burton,et al. Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.
[42] H. Fleury,et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.
[43] R. Doms,et al. Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein , 2001, Journal of Virology.
[44] S. Zolla-Pazner. Improving on nature: focusing the immune response on the V3 loop. , 2006, Human antibodies.
[45] H. Schuitemaker,et al. In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 Antagonists , 2004, Journal of Virology.
[46] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[47] P. Jolly,et al. Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates. , 2000, Virology.
[48] M. Salimans,et al. Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.
[49] B. Korber,et al. Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques , 2006, Journal of Virology.
[50] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.